Ascellahealth hub partnership with abeona therapeutics® supports launch success of novel cell-based gene therapy and access to treatment for rare disease patients

Berwyn, pa., july 29, 2025 (globe newswire) -- ascellahealth, a global partner delivering customizable solutions to support the specialty pharmaceutical industry, highlights the value of its hub partnership with abeona therapeutics inc. (nasdaq: abeo) in the successful pre-and-post launch commercialization of zevaskyn™, an fda-approved cell-based gene therapy.
ABEO Ratings Summary
ABEO Quant Ranking